Literature DB >> 29610119

Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience.

Rahul Sehgal1, Erik J Stratman2, Jonathan E Cutlan3.   

Abstract

Biologic agents are regarded as an effective treatment for a variety of autoimmune diseases. These drugs have an acceptable safety and tolerability profile, although an increasing number of autoimmune conditions have been reported with their use. Additionally, a variety of cutaneous diseases have been associated with their use. Here we report our experience of adverse cutaneous events with the use of biologic agents. An alternative explanation for patients presenting with adverse cutaneous events including drug interactions must be carefully investigated.
© 2018 Marshfield Clinic.

Entities:  

Keywords:  Adverse drug events; Anti-TNF therapy; Autoimmune disease; Biologic agents; Cutaneous vasculitis

Mesh:

Substances:

Year:  2018        PMID: 29610119      PMCID: PMC6108513          DOI: 10.3121/cmr.2017.1364

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  31 in total

1.  Paradoxical reactions to targeted biological treatments: A way to treat and trigger?

Authors:  Alexandra M G Brunasso; Martin Laimer; Cesare Massone
Journal:  Acta Derm Venereol       Date:  2010-03       Impact factor: 4.437

2.  Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

Authors:  P P Sfikakis; J N Boletis; S Lionaki; V Vigklis; K G Fragiadaki; A Iniotaki; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  2005-02

3.  Development of pyoderma gangrenosum during therapy with infliximab.

Authors:  Natalia Jaimes-López; Verónica Molina; Juan E Arroyave; Luz A Vasquez; Ana C Ruiz; Rodrigo Castaño; Mario H Ruiz
Journal:  J Dermatol Case Rep       Date:  2009-08-24

4.  Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome.

Authors:  A V Marzano; D Fanoni; E Antiga; P Quaglino; M Caproni; C Crosti; P L Meroni; M Cugno
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

5.  Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids.

Authors:  C Bonifati; E Trento; P Cordiali Fei; L Muscardin; A Amantea; M Carducci
Journal:  Clin Exp Dermatol       Date:  2005-11       Impact factor: 3.470

6.  Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.

Authors:  Elena B Hawryluk; Katy R Linskey; Lyn M Duncan; Rosalynn M Nazarian
Journal:  J Cutan Pathol       Date:  2012-05       Impact factor: 1.587

7.  Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

Authors:  Niveditha Mohan; Evelyne T Edwards; Thomas R Cupps; Nancy Slifman; Jong-Hoon Lee; Jeffrey N Siegel; M Miles Braun
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

8.  IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells.

Authors:  Wendy A Goodman; Alan D Levine; Jessica V Massari; Hideaki Sugiyama; Thomas S McCormick; Kevin D Cooper
Journal:  J Immunol       Date:  2009-07-31       Impact factor: 5.422

9.  Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Authors:  Marcel Flendrie; Wynand H P M Vissers; Marjonne C W Creemers; Elke M G J de Jong; Peter C M van de Kerkhof; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2005-04-04       Impact factor: 5.156

Review 10.  Neutrophilic skin lesions in autoimmune connective tissue diseases: nine cases and a literature review.

Authors:  Estelle Hau; Marie-Dominique Vignon Pennamen; Maxime Battistella; Anne Saussine; Maud Bergis; Benedicte Cavelier-Balloy; Michel Janier; Florence Cordoliani; Martine Bagot; Michel Rybojad; Jean-David Bouaziz
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

View more
  4 in total

Review 1.  Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.

Authors:  Eun Hye Park; Eun Young Lee; Kichul Shin; Hyoun-Ah Kim
Journal:  Rheumatol Int       Date:  2019-10-09       Impact factor: 2.631

2.  Molecular Insights of Nickel Binding to Therapeutic Antibodies as a Possible New Antibody Superantigen.

Authors:  Chinh Tran-To Su; Wai-Heng Lua; Jun-Jie Poh; Wei-Li Ling; Joshua Yi Yeo; Samuel Ken-En Gan
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

Review 3.  Vasculitis induced by biological agents used in rheumatology practice: A systematic review.

Authors:  Camila da Silva Cendon Duran; Adriane Souza da Paz; Mittermayer Barreto Santiago
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

Review 4.  Cutaneous sıde-effects of the potential COVID-19 drugs.

Authors:  Ümit Türsen; Belma Türsen; Torello Lotti
Journal:  Dermatol Ther       Date:  2020-05-22       Impact factor: 3.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.